1960
DOI: 10.1001/archsurg.1960.01300050146026
|View full text |Cite
|
Sign up to set email alerts
|

The Obituary of Ivalon Arterial Grafts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1964
1964
2003
2003

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…We have shown that the absence of PECAM-1 can attenuate neovascularization, extracellular matrix deposition and leukocyte accumulation in and around these sterile, inert PVA implants. Although PVA sponges have been retired from their use as human arterial grafts, 46 they are widely used to study cellular components of foreign body reaction: angiogenesis, granuloma formation, and extracellular matrix deposition. 45,47,48 It will be of great interest to pursue potential clinical applications of this finding, including the use of local PECAM-1-blocking reagents (anti-sense oligonucleotides, PECAM-1 antibodies, recombinant PECAM-1 peptides) coupled to synthetic prosthetic devices or local delivery of such reagents to the site(s) of prosthetic implants to ameliorate the fibrotic complications that result in functional compromise of prosthetic devices including cardiac and vascular patches and arteriovenous shunt prosthetics.…”
Section: Discussionmentioning
confidence: 99%
“…We have shown that the absence of PECAM-1 can attenuate neovascularization, extracellular matrix deposition and leukocyte accumulation in and around these sterile, inert PVA implants. Although PVA sponges have been retired from their use as human arterial grafts, 46 they are widely used to study cellular components of foreign body reaction: angiogenesis, granuloma formation, and extracellular matrix deposition. 45,47,48 It will be of great interest to pursue potential clinical applications of this finding, including the use of local PECAM-1-blocking reagents (anti-sense oligonucleotides, PECAM-1 antibodies, recombinant PECAM-1 peptides) coupled to synthetic prosthetic devices or local delivery of such reagents to the site(s) of prosthetic implants to ameliorate the fibrotic complications that result in functional compromise of prosthetic devices including cardiac and vascular patches and arteriovenous shunt prosthetics.…”
Section: Discussionmentioning
confidence: 99%